Trial · NCT02996097
Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids
NCT02996097, Not applicable, Completed, Johns Hopkins University; results first posted 2019-04-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids. Trials, record NCT02996097. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02996097
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids
- NCT number
- NCT02996097
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 30 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Keloid
- Interventions
- The Lutronic electronic carbon dioxide (eCO2) Plus laser system, Intralesional Triamcinolone Acetonide
- First posted
- 2016-12-19
- Last updated
- 2020-12-17
- Results first posted
- 2019-04-25
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Change in Composite Observer Score for Patient and Observer Scar Assessment Scale (POSAS) | Once every 4 weeks for 16 weeks | Data from POSAS Observer Scale will be collected and reported to assess vascularity, pigmentation, thickness, relief, pliability, and surface area of the keloids chosen for the research study. Total score range: 6-60; Higher scores mean a worse outcome. Mean composite score of the final visit was compared to the mean baseline score. |
| Primary | Mean Change in Composite Patient Score for Patient and Observer Scar Assessment Scale (POSAS) | Once every 4 weeks for 16 weeks | Data from POSAS Observer Scale will be collected and reported to assess vascularity, pigmentation, thickness, relief, pliability, and surface area of the keloids chosen for the research study. Total score range: 6-60; Higher scores mean a worse outcome. Mean composite score of the final visit was compared to the mean baseline score. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Change in Composite Observer Score for Patient and Observer Scar Assessment Scale (POSAS) | Once every 4 weeks for 16 weeks | Analyzed 19 participants who completed the study (5 visits) in addition to the 3 participants who completed 3 of 5 visits to provide enough data for this analysis. | score on a scale | MEAN |
| PRIMARY | Mean Change in Composite Patient Score for Patient and Observer Scar Assessment Scale (POSAS) | Once every 4 weeks for 16 weeks | Analyzed 19 participants who completed the study (5 visits) in addition to the 3 participants who completed 3 of 5 visits to provide enough data for this analysis. | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change in Composite Observer Score for Patient and Observer Scar Assessment Scale (POSAS) | CO2 Ablative Laser PLUS Intralesional Triamcinolone Acetonide | -9.5 | 95% Confidence Interval -12.2 to -6 | score on a scale | |
| Mean Change in Composite Observer Score for Patient and Observer Scar Assessment Scale (POSAS) | Intralesional Triamcinolone Acetonide Only | -8.9 | 95% Confidence Interval -11.7 to -6 | score on a scale | |
| Mean Change in Composite Patient Score for Patient and Observer Scar Assessment Scale (POSAS) | CO2 Ablative Laser PLUS Intralesional Triamcinolone Acetonide | -22.6 | 95% Confidence Interval -28.5 to -16.7 | score on a scale | |
| Mean Change in Composite Patient Score for Patient and Observer Scar Assessment Scale (POSAS) | Intralesional Triamcinolone Acetonide Only | -18.8 | 95% Confidence Interval -24.5 to -13.2 | score on a scale |
Source ClinicalTrials.gov
Participant flow8
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | CO2 Ablative Laser PLUS Intralesional Triamcinolone Acetonide | 30 | 30 |
| Overall Study | STARTED | Intralesional Triamcinolone Acetonide Only | 30 | 30 |
| Overall Study | Per Protocol Population | CO2 Ablative Laser PLUS Intralesional Triamcinolone Acetonide | 22 | 22 |
| Overall Study | Per Protocol Population | Intralesional Triamcinolone Acetonide Only | 22 | 22 |
| Overall Study | COMPLETED | CO2 Ablative Laser PLUS Intralesional Triamcinolone Acetonide | 19 | 19 |
| Overall Study | COMPLETED | Intralesional Triamcinolone Acetonide Only | 19 | 19 |
| Overall Study | NOT COMPLETED | CO2 Ablative Laser PLUS Intralesional Triamcinolone Acetonide | 11 | 11 |
| Overall Study | NOT COMPLETED | Intralesional Triamcinolone Acetonide Only | 11 | 11 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | CO2 Ablative Laser +/- Intralesional Triamcinolone Acetonide | 0 | 30 |
| Total, other adverse events | CO2 Ablative Laser +/- Intralesional Triamcinolone Acetonide | 0 | 30 |
| Total, serious adverse events | CO2 Ablative Laser +/- Intralesional Triamcinolone Acetonide | 0 | 30 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02996097
GET https://conductscience.org/api/trials/v1/NCT02996097/registered